Immunology
Meteor Biotech opens site at UCLA to support biotech research
June 11, 2025Biotech/start-up, Research and Development, Sales and Marketing Devices, Immunology, Meteor Biotech, Oncology, Pharmacy, University of California Los Angeles, cell sorting technology, clinical trials, research facility
South Korean spatial omics specialist, Meteor Biotech, has announced the opening of its first international office at the California NanoSystems …
Takeda presents positive results from trial of chronic kidney disease treatment
June 10, 2025Research and Development European Renal Association, Immunology, Nephrology, Takeda, autoimmune disease, immunoglobulin A nephropathy (IgAN), kidney disease
Takeda Pharmaceuticals has announced positive results from a proof-of-concept study of mezagitamab (TAK-079) to treat patients with primary immunoglobulin A …
Hansa Biopharma to host investor event on Guillain-Barré Syndrome to accelerate research
June 10, 2025Conferencing, Events & Incentives, Interactive Conferences, Medical Communications, Research and Development, Sales and Marketing Guillain-Barré syndrome, Hansa Biopharma, Immunology, Neurology, investor event
Hansa Biopharma (Hansa) will host a virtual investor event on Guillain-Barré syndrome (GBS) on 16 June 2025. The webcast aims …
Sanofi to acquire Blueprint, advancing therapy for rare immunological diseases
June 3, 2025Mergers and Acquisitions, Research and Development Blueprint Medicines, Immunology, Rare Diseases, Sanofi, advanced systemic mastocytosis (ASM), indolent systemic mastocytosis (ISM), rare immunological diseases
Sanofi and Blueprint Medicines Corporation, a US biopharma, have entered into an agreement under which Sanofi will acquire Blueprint. This …
Hansa Biopharma data demonstrates potential of imlifidase in Guillain-Barré syndrome
May 15, 2025Research and Development Guillain-Barré Syndrome (GBS), Hansa Biopharma, Immunology, Peripheral Nerve Society (PNS) Annual Meeting, Rare Diseases
Hansa Biopharma will present data from its 15-HMedIdeS-09 phase 2 study of imlifidase for treating Guillain-Barré syndrome (GBS) at the …
Neogap Therapeutics selected to join EIC Soft-landing Programme, supporting international growth
May 15, 2025Medical Communications, Sales and Marketing Corporate, European Innovation Council (EIC), Immunology, Neogap Therapeutics, US pharma market, biotech, immunotherapy
Swedish biotech company, Neogap Therapeutics, has been selected to participate in the EIC Soft-landing Programme for Healthcare and Life Sciences …
Hansa Biopharma appoints Maria Törnsén as chief operating officer and US president
May 14, 2025Research and Development Corporate, Hansa Biopharma, Immunology, Pharmacy, biopharma, chief operating officer (COO), immunology
Swedish biopharma company Hansa Biopharma has appointed Maria Törnsén as chief operating officer (COO) and president US effective 19 May …
Alchemab Therapeutics signs $415m licensing agreement for ALS programme with Eli Lilly
May 7, 2025Mergers and Acquisitions Alchemab Therapeutics, Corporate, Eli Lilly and Company, Immunology, M&A, als, immunology, neurodegenerative conditions
Alchemab Therapeutics, an immunotherapy-focused biopharma company, has entered a licensing agreement with Eli Lilly and Company (Lilly) for ATLX-1282, its …
McDavid Stilwell appointed as CFO of CPTx
April 28, 2025Research and Development CPTx, Immunology, Oncology, appointment, cfo, therapeutics
CPTx, a German biotech company focused on single-stranded DNA therapeutics, has announced the appointment of McDavid Stilwell as chief financial …
AAX Biotech aims to enhance growth with two new appointments
April 10, 2025Business Development, Recruitment, Research and Development AAX Biotech, Immunology, Oncology, R&D development, antibody therapeutics, business development
AAX Biotech has appointed Ionut Gabriel Dumitru (pictured left) as senior scientist and Kushal Sejwal (pictured right) as business developer, …
Pharming Group doses first patient in phase 2 trial of leniolisib in CVID
March 26, 2025Clinical Trial Services, Research and Development CVID, Immunology, Pharming Group, clinical trial, common variable immunodeficiency, immunodeficiency
Pharming Group has announced that the first patient has been dosed in a phase 2 clinical trial evaluating leniolisib in …
Takeda announces launch of Framework to help support patient access to life-extending combination treatments
February 25, 2025Business Services Cancer, HIV/AIDS, Immunology, NHS, NICE, Oncology, Takeda, VPAG, patient access
The Conceptual Implementation Framework outlines critical points within the UK healthcare access ecosystem to help improve the introduction of combination …
Santhera Pharmaceuticals announces LIONHEART study results for corticosteroid vamorolone
October 1, 2024Research and Development Cardiology, Duchenne Muscular Dystrophy, Immunology, Santhera Pharmaceuticals, clinical studies
Santhera Pharma has announced the results of its LIONHEART study, which evaluated vamorolone – a corticosteroid – and confirmed its …
Amferia closes €1,2 million investment to combat resistant bacterial infections
September 3, 2024Research and Development Amferia, Chalmers Ventures, Dressings, hosiery & appliances, Hospital Management, Immunology, antimicrobial, investment, peptides
Swedish medtech company Amferia announces the successful completion of its latest investment round, boosting its mission to combat wound infections. …
The National Institute for Health and Care Excellence announce technology appraisal guidance recommending risankizumab for adult patients with moderate to severe ulcerative colitis
August 29, 2024Research and Development AbbVie, Crohns, Gastrointestinal tract, Immunology, NICE, approval, ulcerative colitis
The National Institute for Health and Care Excellence (NICE) have recommended adult patients in England or Wales with moderately or …
